Monoclonal antibody · Antagonist of endoglin (CD105) (ENG) · developed by Tracon Pharmaceuticals
Phase 2Most advanced trial
1Registered trials
What is Carotuximab?
Carotuximab is a human/murine chimeric monoclonal antibody that binds endoglin (CD105), a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells. By binding endoglin it may inhibit tumor angiogenesis and reduce tumor cell proliferation. It is studied in castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.